The 2019 Annual NEALS Meeting will take place Oct. 2-4, 2019 in Clearwater Beach, Fla.
SCOTTSDALE, Ariz., SEPTEMBER 12, 2019 – Aural Analytics, Inc., a privately-held digital health company focused on building the world’s most advanced speech analytics platform, today announced data results from a clinical trial powered by the Company’s speech analytics platform technology will be presented at the 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting. The 2019 Annual NEALS Meeting will take place October 2 – 4 in Clearwater Beach, Fla.
Gabriela Stegmann, Ph.D., data scientist at Aural Analytics, adjunct professor at Keiser University and adjunct professor at Arizona State University will present abstract ID56: “Using voice analysis to track ALS progress in clinical trials with a mobile app” in a poster session on Thurs., Oct. 3, 2019 from 4:00 – 6:00 p.m., ET in the Opal Sands Foyer at the Opal Sands Resort in Clearwater Beach, Fla. Copies of the poster will be available upon request at the meeting.
The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) was founded in 1995 with nine academic clinical centers in the New England area and has grown to 128 research centers committed to performing research in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND). The NEALS mission is to translate scientific advances into new treatments for people with ALS and MND as rapidly as possible. NEALS functions as an academic research consortium, a contracted research organization and a resource tool for ALS community.
The 18th Annual NEALS Meeting will host over 400 NEALS members, foundation partners, company representatives and ALS researchers. The 2019 NEALS Meeting will feature research updates, member presentations, abstract poster session, a Science Symposium focused on TDP-43, and numerous networking opportunities. For more information, please visit: https://www.neals.org.
About The Aural Analytics Technology Platform
Aural Analytics has built a model-driven, transparent analytics engine based on decades of expertise in speech neuroscience that has been clinically validated to the highest standard in several disease indications. The cloud-based software platform combines beautiful mobile design with speech signal processing and cognitive linguistic analysis together into one powerful set of APIs that are easily extensible across the continuum of care. The platform is disease, location, language and device agnostic and has been deployed in eight languages and on four continents. Users can leave samples from anywhere in the world, any time.
The platform uses speech to extract finite but clinically relevant measures by tapping directly into various nervous system functions. The mobile first, patient centric product suite is easy to use, low cost and analytics are available in real-time. The analysis gives deep insight into key areas known to change with disease including, but not limited to, motor control, respiratory support and function and all aspects of cognitive linguistics. Aural Analytics’ solutions have been used extensively in interventional clinical trials, observational research studies and several clinical and consumer settings.
About Aural Analytics, Inc.
Aural Analytics, Inc. is a privately held digital health company developing the world’s most advanced speech analytics platform, built on a foundation of 25 years of speech neuroscience research and data. The Company’s platform technology is based on pioneering research from Arizona State University and reinforced by multiple high-caliber peer-reviewed publications from co-founders Julie Liss, Ph.D. and Visar Berisha, Ph.D. Winners of the 2017 Global SCRIP Award for Best Technology in Clinical Trials, Aural Analytics’ first-to-market technology platform powers health applications all over the world. The Company maintains headquarters in Scottsdale, Ariz. For more information, please visit auralanalytics.com or follow Aural Analytics on Twitter, LinkedIn, Medium and Facebook.
Consilium Strategic Communications US Inc.